Articles from Eleusis

ST VINCENT AND THE GRENADINES, Caribbean, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Eleusis, the world’s first legal luxury psychedelic immersion, using DMTx protocols, will officially debut in March 2026 on the island of Bequia in Saint Vincent and the Grenadines. Built on a single foundational principle — safety first — Eleusis offers a licensed, research immersion in a physician-supervised environment, set within a private tropical wellness sanctuary. Eleusis is accepting applications for the March 2026 cohort, with private inquiries welcomed.

Eleusis Holdings Ltd announced today it has received a Notice of Allowance for its proprietary psilocin salt form and accompanying formulations from the US Patent and Trademark Office. This salt form and formulations are being developed as Eleusis’ lead drug candidate, ELE-Psilo.

Eleusis, a clinical-stage life science company that aims to unlock the therapeutic potential of psychedelics, and Silver Spike Acquisition Corp. II (“SPKB”) (NASDAQ: SPKB/SPKBU/SPKBW), a publicly traded special purpose acquisition company (“SPAC”) sponsored by an affiliate of Silver Spike Capital (“Silver Spike”), announced today that they have signed a definitive business combination agreement expected to make Eleusis a public company. Upon the close of the transaction, the combined company will be operated through Eleusis Inc., a new holding company, and will apply to have its common stock listed on Nasdaq under the symbol “ELEU.”